Shandong Wit Dyne Health Co.,Ltd.

Equities

000915

CNE000000Z28

Pharmaceuticals

End-of-day quote Shenzhen S.E. 18:00:00 2024-05-13 EDT 5-day change 1st Jan Change
35.63 CNY -0.78% Intraday chart for Shandong Wit Dyne Health Co.,Ltd. -2.28% +23.03%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shandong Wit Dyne Health Co.,Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 16 May 2024 CI
Shandong Wit Dyne Health Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shandong Wit Dyne Health Co.,Ltd. Proposes Final Cash Dividend for the Year 2023 CI
Shandong Wit Dyne Health Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
WIT Dyne Health Unit's Epalrestat Tablets Passes Regulator's Consistency Evaluation MT
Shandong Wit Dyne Health Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shandong Wit Dyne Health Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shandong Shanda Wit Science and Technology Co., Ltd. Approves Cash Dividend for the Year of 2022, Payable on 12 May 2023 CI
Shandong Shanda Wit Science and Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shandong Shanda Wit Science and Technology Co., Ltd. Proposes Profit Distribution for 2022 CI
Shandong Shanda Wit Science and Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shandong Shanda Wit Science and Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shandong Shanda Wit Science and Technology Co., Ltd.(XSEC:000915) added to S&P Global BMI Index CI
Shandong Shanda Wit Science and Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Shandong Shanda Wit Science and Technology Co., Ltd. Approves Cash Dividend for 2021 CI
Shandong Shanda Wit Science and Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
WIT Dyne Health Lifts 2021 Dividend on Double-Digit Earnings Growth MT
Shandong Shanda Wit Science and Technology Co., Ltd. Proposes Final Cash Dividend for the Year 2021 CI
Shandong Shanda Wit Science and Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Shandong Shanda Wit Science and Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Shandong Shanda Wit Science and Technology Co., Ltd. Announces Executive Changes CI
Shandong Shanda Wit Science and Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Shandong Shanda Wit Science and Technology Co., Ltd. Announces 2020 Final Distribution Plan, Payable on 01 June 2021 CI
Shandong Shanda Wit Science and Technology : Wit Dyne Health Adopts New Name MT
Shandong Shanda Wit Science and Technology Co., Ltd. has Changed its Name to Shandong Wit Dyne Health Co., Ltd CI
Chart Shandong Wit Dyne Health Co.,Ltd.
More charts
Shandong WIT Dyne Health Co Ltd, formerly Shandong Shanda Wit Science and Technology Co Ltd, is a China-based company principally engaged in pharmaceutical and environment protection businesses. The Company manufactures and sells pharmaceutical products, food and supplies for children through its subsidiary. Its environment protection business includes the manufacture and sale of chlorine dioxide equipment and products, flue gas desulfurization services for power plants and energy saving services. The Company is also involved in manufacture of electronic information products, owned property rental, education services and new material business, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
35.63
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 000915 Stock
  4. News Shandong Wit Dyne Health Co.,Ltd.
  5. WIT Dyne Health Unit's Epalrestat Tablets Passes Regulator's Consistency Evaluation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW